Beam Therapeutics (BEAM) FCF Margin (2019 - 2026)

Beam Therapeutics (BEAM) has 8 years of FCF Margin data on file, last reported at 411.95% in Q1 2026.

• On a quarterly basis, FCF Margin rose 101976.0% year-over-year to 411.95% in Q1 2026; TTM through Mar 2026 was 225.7%, a 32928.0% increase from a year earlier, with the FY2025 full-year figure at 247.86%, up 30014.0% from the prior year.
• FCF Margin for Q1 2026 stood at 411.95%, down from 71.37% in the prior quarter.
• Over the last five years, FCF Margin for BEAM reached as high as 2409.68% in Q1 2022 and fell as low as 1431.71% in Q1 2025.
• Historically, FCF Margin has averaged 413.59% across 5 years, with a median of 501.33% in 2023.
• Across the five-year window, FCF Margin soared 99979131 bps in 2022 and sank 288816 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 386.54% in 2022, then surged by 113 bps to 51.81% in 2023, then tumbled by 593 bps to 255.26% in 2024, then soared by 72 bps to 71.37% in 2025, then slumped by 477 bps to 411.95% in 2026.
• Per Business Quant data, the three most recent FCF Margin figures were 411.95% in Q1 2026, 71.37% in Q4 2025, and 808.46% in Q3 2025.